Risk of hospitalization and death from COVID-19 infection in patients with chronic plaque psoriasis receiving a biologic treatment and renal transplant recipients in maintenance immunosuppressive treatment.
作者信息
Gisondi Paolo, Zaza Gianluigi, Del Giglio Micol, Rossi Mattia, Iacono Valentina, Girolomoni Giampiero
机构信息
Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy.
Section of Nephrology, Department of Medicine, University of Verona, Verona, Italy.
出版信息
J Am Acad Dermatol. 2020 Jul;83(1):285-287. doi: 10.1016/j.jaad.2020.04.085. Epub 2020 Apr 21.
Abstract
摘要
相似文献
1
Risk of hospitalization and death from COVID-19 infection in patients with chronic plaque psoriasis receiving a biologic treatment and renal transplant recipients in maintenance immunosuppressive treatment.接受生物治疗的慢性斑块状银屑病患者以及接受维持性免疫抑制治疗的肾移植受者感染新型冠状病毒肺炎（COVID-19）后住院和死亡的风险。
J Am Acad Dermatol. 2020 Jul;83(1):285-287. doi: 10.1016/j.jaad.2020.04.085. Epub 2020 Apr 21.
2
The impact of the COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the Northern Italy experience.2019年冠状病毒病大流行对接受生物疗法治疗的慢性斑块状银屑病患者的影响：意大利北部的经验。
Br J Dermatol. 2020 Aug;183(2):373-374. doi: 10.1111/bjd.19158. Epub 2020 May 28.
3
A single center observational study of the clinical characteristics and short-term outcome of 20 kidney transplant patients admitted for SARS-CoV2 pneumonia.一项关于 20 例因 SARS-CoV2 肺炎入院的肾移植患者的临床特征和短期结局的单中心观察性研究。
Kidney Int. 2020 Jun;97(6):1083-1088. doi: 10.1016/j.kint.2020.04.002. Epub 2020 Apr 9.
4
Treatment discontinuation and rate of disease transmission in psoriasis patients receiving biologic therapy during the COVID-19 pandemic: A Canadian multicenter retrospective study.2019年冠状病毒病大流行期间接受生物治疗的银屑病患者的治疗中断情况及疾病传播率：一项加拿大多中心回顾性研究
J Am Acad Dermatol. 2020 Oct;83(4):1212-1214. doi: 10.1016/j.jaad.2020.07.021. Epub 2020 Jul 15.
5
COVID-19 in a Kidney Transplant Patient.一名肾移植患者的新型冠状病毒肺炎
Eur Urol. 2020 Jun;77(6):769-770. doi: 10.1016/j.eururo.2020.03.036. Epub 2020 Apr 6.
6
Risk of COVID-19 in dermatologic patients receiving long-term immunomodulatory therapy.接受长期免疫调节治疗的皮肤病患者感染新型冠状病毒肺炎的风险
J Am Acad Dermatol. 2020 Oct;83(4):1215-1218. doi: 10.1016/j.jaad.2020.06.999. Epub 2020 Jul 2.
7
Coronavirus Disease 2019 Pneumonia in Immunosuppressed Renal Transplant Recipients: A Summary of 10 Confirmed Cases in Wuhan, China.新型冠状病毒肺炎合并免疫抑制的肾移植受者肺炎：中国武汉 10 例确诊病例总结
Eur Urol. 2020 Jun;77(6):748-754. doi: 10.1016/j.eururo.2020.03.039. Epub 2020 Apr 18.
8
COVID-19 in long-term liver transplant patients: preliminary experience from an Italian transplant centre in Lombardy.长期肝移植患者中的新型冠状病毒肺炎：来自意大利伦巴第地区一家移植中心的初步经验。
Lancet Gastroenterol Hepatol. 2020 Jun;5(6):532-533. doi: 10.1016/S2468-1253(20)30116-3. Epub 2020 Apr 9.
9
COVID-19 and biologics for psoriasis: A high-epidemic area experience-Bergamo, Lombardy, Italy.新型冠状病毒肺炎与银屑病生物制剂：高流行地区的经验——意大利伦巴第大区贝加莫市
J Am Acad Dermatol. 2020 Jul;83(1):292-294. doi: 10.1016/j.jaad.2020.04.165. Epub 2020 May 6.
10
The risk of respiratory tract infections and symptoms in psoriasis patients treated with interleukin 17 pathway-inhibiting biologics: A meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic.接受白细胞介素17通路抑制生物制剂治疗的银屑病患者发生呼吸道感染和症状的风险：对COVID-19大流行期间决策相关关键试验的荟萃估计。
J Am Acad Dermatol. 2020 Aug;83(2):677-679. doi: 10.1016/j.jaad.2020.05.035. Epub 2020 May 19.
引用本文的文献
1
COVID-19 Among Patients with Psoriasis: A Single-Center Retrospective Cross-Sectional Study.银屑病患者中的新型冠状病毒肺炎：一项单中心回顾性横断面研究。
Infect Dis Clin Microbiol. 2023 Jun 23;5(2):127-135. doi: 10.36519/idcm.2023.192. eCollection 2023 Jun.
2
Psoriasis and biological drugs at the time of SARS-CoV-2 infection: a mini review outlining risk of infection, seroprevalence, and safety and efficacy of the BNT162b2 vaccine.COVID-19 感染时的银屑病和生物药物：概述感染风险、血清流行率以及 BNT162b2 疫苗安全性和有效性的小型综述。
Front Immunol. 2024 Jan 30;15:1354729. doi: 10.3389/fimmu.2024.1354729. eCollection 2024.
3
The Impact of Immune-Modulating Treatments for Dermatological Diseases on the Risk of Infection with SARS-CoV-2 and Outcomes Associated with COVID-19 Illness.皮肤科疾病免疫调节治疗对感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2）风险及与冠状病毒病（COVID-19）相关结局的影响
Curr Dermatol Rep. 2023;12(2):45-55. doi: 10.1007/s13671-023-00385-w. Epub 2023 Apr 3.
4
Inflammation Causes Exacerbation of COVID-19: How about Skin Inflammation?炎症导致 COVID-19 恶化：皮肤炎症呢？
Int J Mol Sci. 2022 Oct 14;23(20):12260. doi: 10.3390/ijms232012260.
5
COVID-19 Pandemic Impact on Severe Alopecia Areata Patients.新冠疫情对重度斑秃患者的影响。
Skin Appendage Disord. 2022 May;8(3):195-199. doi: 10.1159/000520422. Epub 2021 Dec 20.
6
The role of gender, race, and ethnicity in psoriasis patients with COVID-19 infection: A cross-sectional study.性别、种族和民族在新冠肺炎感染银屑病患者中的作用：一项横断面研究。
Int J Womens Dermatol. 2022 Mar 21;8(1):e012. doi: 10.1097/JW9.0000000000000012. eCollection 2022 Mar.
7
Novel Therapeutic Approaches to Psoriasis and Risk of Infectious Disease.银屑病的新型治疗方法与传染病风险
Biomedicines. 2022 Jan 21;10(2):228. doi: 10.3390/biomedicines10020228.
8
Management of Psoriasis During the Coronavirus Disease 2019 Pandemic.2019年冠状病毒病大流行期间银屑病的管理
J Clin Aesthet Dermatol. 2021 Sep;14(9):41-44.
9
Updates on Management of Leprosy in the Context of COVID-19 Pandemic: Recommendations by IADVL SIG Leprosy.2019冠状病毒病大流行背景下麻风病管理的最新情况：印度皮肤病学、性病学和麻风病学学会麻风病特别兴趣小组的建议
Indian Dermatol Online J. 2021 Nov 25;12(Suppl 1):S24-S30. doi: 10.4103/idoj.idoj_513_21. eCollection 2021 Nov.
10
COVID-19 and Dermatology in Iran.新型冠状病毒肺炎（COVID-19）与伊朗的皮肤病学
Clin Dermatol. 2021 Jul-Aug;39(4):703-706. doi: 10.1016/j.clindermatol.2021.05.022. Epub 2021 May 18.
本文引用的文献
1
Should biologics for psoriasis be interrupted in the era of COVID-19?在新冠疫情时代，银屑病生物制剂是否应中断使用？
J Am Acad Dermatol. 2020 May;82(5):1217-1218. doi: 10.1016/j.jaad.2020.03.031. Epub 2020 Mar 19.
2
Should patients stop their biologic treatment during the COVID-19 pandemic.在新冠疫情期间，患者是否应该停止生物制剂治疗？
J Dermatolog Treat. 2020 Jun;31(4):317-318. doi: 10.1080/09546634.2020.1742438. Epub 2020 Mar 19.
Zotero 插件